Acutaas Chemicals rallies 13%; hits record high on strong Q2 results
Acutaas Chemicals moved lower in a quarterly results development.
· Business Standard Mkts
Thus far in the calendar year 2026, Acutaas Chemicals' market price has zoomed 116% compared to a 9.4% decline in the Nifty 500 index.
The analysis
Acutaas Chemicals reported movement of 13%, 116% and 9.4%. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -2.2% on the day at ₹3,710.00, and has returned +12.5% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved -1.0% over the same period, so Acutaas Chemicals is running 13.5 points ahead of its peers.
For Acutaas Chemicals, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Acutaas Chemicals (ACUTAAS), in Pharma & Healthcare.
- Over three months: Acutaas Chemicals +12.5% against Pharma & Healthcare -1.0% (13.5 points ahead).
- Trading well above normal today: Acutaas Chemicals at 3.4 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Acutaas ChemicalsACUTAAS · Pharma & Healthcare | ₹3,710.00 | -2.2% | +15.4% | +12.5% | -2.2% | 3.4× | — |
Pharma & Healthcare
1M -3.1% · 3M -1.0%
Acutaas Chemicals
Chemicals
1M -9.6% · 3M -11.8%
Prices as of 28 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore, revenue slips 2%
Reliance Industries Q2 results 2026 date and time: Mukesh Ambani company's quarterly earnings schedule - Expectations
Cipla’s US recovery, biosimilar pipeline key to future growth prospects
OneSource Specialty Pharma shares jump 14% after Q2 results; recover 50% from recent lows
Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore